Sickle cell crisis
Methodology & AI Transparency ⓘ
Sickle cell crisis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Sickle cell crisis (ICD-10-CM D57.00), Anemia, Clotting & Blood Disorders protocols prioritize targeted oral/IV iron in Sickle cell crisis (D57.00: or vitamin repletion) paired with baseline and interval Hemoglobin, Hematocrit & in Sickle cell crisis (D57.00: MCV) assessment.
- 2 Real-world patient consensus: Federal ICD-10-CM code D57.00 categorizes Sickle cell crisis under Anemia, Clotting & Blood Disorders.
- 3 Typical cash cost range: Workup highlights for Sickle cell crisis (D57.00): targeted oral/IV iron in Sickle cell crisis (D57.00: or vitamin repletion).
- 4 Top reported side effects / signs: Longitudinal Sickle cell crisis monitoring tracks Hemoglobin, Hematocrit & in Sickle cell crisis (D57.00: MCV) toward Hgb 13.5–17.0 (M) / 12.0–15.5 (F) g/dL (D57.00).
Ask our AI Specialists anything about Sickle cell crisis
What Is Sickle cell crisis?
For patients presenting with Sickle cell crisis (ICD-10-CM D57.00), Anemia, Clotting & Blood Disorders protocols prioritize targeted oral/IV iron in Sickle cell crisis (D57.00: or vitamin repletion) paired with baseline and interval Hemoglobin, Hematocrit & in Sickle cell crisis (D57.00: MCV) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Sickle cell crisis (D57.00) center on impaired erythropoiesis from in Sickle cell crisis (D57.00: iron). targeted blood & anemia interventions aim to normalize Hemoglobin, Hematocrit & in Sickle cell crisis (D57.00: MCV).
Common Symptoms & Clinical Signs
- • Presentation of Sickle cell crisis (D57.00): exertional fatigue, reduced in Sickle cell crisis (D57.00: stamina, pale conjunctiva,)
- • Secondary Sickle cell crisis clinical sign: restless legs, ice in Sickle cell crisis (D57.00: craving)
- • Symptom flares in Sickle cell crisis correlating with Hemoglobin, Hematocrit & in Sickle cell crisis (D57.00: MCV) deviation outside Hgb 13.5–17.0 (M) / 12.0–15.5 (F) g/dL (D57.00)
- • Functional blood & anemia impact requiring targeted oral/IV iron in Sickle cell crisis (D57.00: or vitamin repletion) evaluation (D57.00)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Sickle cell crisis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D57.00 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Anemia, Clotting & Blood Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Hemoglobin, Hematocrit & in Sickle cell crisis (D57.00: MCV) | Hgb 13.5–17.0 (M) / 12.0–15.5 (F) g/dL (D57.00) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin & in Sickle cell crisis (D57.00: Transferrin Saturation) | Ferritin 50–150 ng/mL; TSAT 20%–45% (D57.00) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Vitamin B12, Folate in Sickle cell crisis (D57.00: & Reticulocyte Count) | B12 > 500 pg/mL; appropriate marrow response (D57.00) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Sickle cell crisis
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| L-Glutamine L-Glutamine Generic • RxCUI 1869684 | Amino Acid | 90% | $2.8100 | $ 122.31 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sickle cell crisis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Benefits and safety of ferric citrate hydrate compared with sodium ferrous The incidences of nausea and vomiting were significantly lower in the FC treatment groups than in the SF group. International journal of hematology • 2021-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33719027 ↗ |
| Can This Approach Help? Inside the Latest Research on Hydroxyurea for secondary stroke prevention in children with sickle cell anemia No participant had hydroxyurea therapy stopped for myelosuppression. Blood • 2023-02-23 • Phase III Randomized Trial | N = 101 | 88/100 | PMID 36322937 ↗ |
| Can This Approach Help? Inside the Latest Research on Evidence of Crizanlizumab Showing Reductions in Vaso-Occlusive Crises and Opioid Crizanlizumab demonstrated potential benefits in attenuating VOC episodes, irrespective of SCD genotype and prior hydroxyurea use, and in lowering opioid usage. European journal of haematology • 2025-02-15 • Phase III Randomized Trial | N = 112 | 82/100 | PMID 39473076 ↗ |
| Can This Approach Help? Inside the Latest Research on Impaired pubertal development and testicular hormone function in males with The hormonal level assessment of testosterone at baseline and at 24, 48 and 72 h after hCG stimulation showed no significant differences between the groups studied. Blood cells, molecules & diseases • 2015-01-15 • Randomized Controlled Trial | N = 15 | 82/100 | PMID 25190051 ↗ |
Sickle cell crisis Patient Community & “People Like Me” Threads
Filter Sickle cell crisis community threads and patient logs by age, biological sex, dosage, and treatment duration.